Industry insights

Lianbang Signs Deals on Micro Oxygen, Plateau Systems

OxySoothe Editorial

Reported by Chuanguan News

Chengdu Lianbang Medical Technology signed research agreements with Sichuan University and Chengdu University on 5 June 2025, covering micro oxygen concentrator design and high-altitude oxygen system innovation. The agreements were signed at a concept-validation event in Shuangliu where announced investment reached about RMB 500 million.

Keywords: micro oxygen concentrator, high-altitude oxygen, industry-academia research, Chengdu

Chengdu Lianbang Medical Technology signed industry-academia-research agreements with Sichuan University and Chengdu University on 5 June 2025 to work on micro oxygen concentrators and high-altitude oxygen systems, according to a report by Chuanguan News, the Sichuan Daily app.

The agreements were signed at a concept-validation and technology-transfer event in Shuangliu district, where six early-stage projects presented to investors and the total announced investment reached about RMB 500 million.

What the two agreements cover

One agreement covers the design and development of micro oxygen concentrators — units small enough for a single room rather than a ward. The other covers technical innovation for oxygen supply systems in high-altitude environments, where low barometric pressure changes both the oxygen concentration a device can deliver and the way a patient absorbs it.

Lianbang’s general manager assistant, Zhang Zhanqing, described the arrangement as a two-way exchange: the company brings a specific engineering problem and a route to market, the universities bring research capacity and laboratory equipment, and both sides end up with something they could not have produced alone.

That framing is worth taking literally. Industry-academia agreements in China are often announced and never heard from again; the ones that produce something usually have three features — a named project with a deliverable, a company engineer assigned to it, and a defined point at which the university’s IP is licensed or assigned. A memorandum without those three is a press release.

Why micro units and high altitude

Both directions point away from the hospital plant that has historically been Lianbang’s core business. A hospital buys a PSA plant sized in tens of cubic metres per hour, installed in a plant room and connected to a pipeline. A micro unit is a consumer-adjacent product: smaller flows, lower pressure, quieter, and sold in larger numbers through a different channel.

High-altitude oxygen is a related but distinct engineering problem. At 3,500 metres the ambient pressure is roughly two-thirds of sea level, so a concentrator that delivers 90% oxygen at sea level still delivers a lower partial pressure of oxygen to the patient. Systems for plateau hotels and clinics therefore combine concentration with slight pressurisation, or deliver higher flows to compensate — which is why the plateau product line looks different from the hospital line.

The commercial logic is straightforward. China’s plateau regions receive tens of millions of visitors a year, and altitude-related sleep disruption is common enough that hotels in Lhasa, Shangri-La and Xining market oxygen as a room feature. A device that can be installed in a guest room, run quietly overnight and serviced by hotel staff is a different product from a medical gas plant, and it needs different research.

The wider event

The 5 June event was organised by the Shuangliu science and technology bureau, the Chengdu Xingu service bureau and the Sichuan Association for Science and Technology Innovation, and hosted at the airport-zone exhibition centre in Shuangliu.

Two concept-validation projects signed at the same event: a palm-vein biometric identification technology and a graphene-modified silicon-carbon anode material. The palm-vein project, developed by Chengdu Weidun Yunmai Technology, reported a false rejection rate below 0.01%, a false acceptance rate below 0.0001% and recognition in under 90 milliseconds — figures that matter because a biometric system that rejects legitimate users is as unusable as one that admits impostors.

Shuangliu operates what it describes as southwest China’s first concept-validation centre for electronic information, offering prototype development and risk assessment to early-stage research projects. The model is a filter: most laboratory results are not commercially viable, and paying for a structured assessment is cheaper than paying for a failed factory.

What to watch

For distributors, the signal is that Lianbang is investing in the small-format end of the market while keeping its hospital systems business. That usually means a future catalogue with two tiers: engineered plants sold project by project, and packaged units sold through partners.

The question to ask a supplier in this position is which factory will build the new product and whether its quality system covers it. A university agreement produces a design; a production line produces a product, and the two are rarely ready on the same date.

Source: Chuanguan News (Sichuan Daily), 5 June 2025 — https://cbgc.scol.com.cn/news/6387253

Tell us your needs

We can tailor a solution for you